Affinity Asset Advisors, LLC Chinook Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $12.2 Million - $25.3 Million	-655,004 Reduced 67.11%	321,017 $12.3 Million
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $3.4 Million - $4.23 Million	157,986 Added 19.31%	976,021 $22.6 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $75,209 - $110,411	4,037 Added 0.5%	818,035 $21.4 Million
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $2.16 Million - $2.89 Million	-123,570 Reduced 13.18%	813,998 $16 Million
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $1.16 Million - $1.74 Million	92,413 Added 10.93%	937,568 $16.4 Million
Q1 2022 May 13, 2022	BUY	$12.02 - $16.69 $3.49 Million - $4.84 Million	290,000 Added 52.24%	845,155 $13.8 Million
Q4 2021 Feb 11, 2022	BUY	$10.69 - $16.83 $5.14 Million - $8.09 Million	480,814 Added 646.77%	555,155 $9.06 Million
Q3 2021 Nov 12, 2021	SELL	$11.5 - $14.86 $1.45 Million - $1.87 Million	-125,659 Reduced 62.83%	74,341 $949,000
Q2 2021 Aug 13, 2021	BUY	$13.6 - $18.98 $340,000 - $474,500	25,000 Added 14.29%	200,000 $2.82 Million
Q1 2021 May 14, 2021	BUY	$14.17 - $19.11 $354,250 - $477,750	25,000 Added 16.67%	175,000 $2.72 Million
Q4 2020 Feb 12, 2021	BUY	$11.9 - $20.91 $1.79 Million - $3.14 Million	150,000 New	150,000 $2.38 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.